Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance.

摘要: // Chao Shang 1, 2 , Lin Sun 3 Jiale Zhang Bochao Zhao Xiuxiu Chen Huimian Xu Baojun Huang 1 Department of Neurobiology, College Basic Medicine, China Medical University, Shenyang, 110001, Surgical Oncology, First Affiliated Hospital, 110004, Gastrointestinal Surgery, Dalian Municipal Central Dalian, 116033, Correspondence to: Huang, email: huang_bj@163.com Keywords: long noncoding RNA, CASC9, gastric cancer, malignancy, chemotherapy resistance Received: December 09, 2016      Accepted: January 17, 2017      Published: 27, 2017 ABSTRACT Cancer Susceptibility Candidate 9 (CASC9) is a novel gene generating non-coding RNA (lncRNA) with oncogenic potential that was first identified in esophageal cancer. In this study, we have found CASC9 overexpressed cancer (GC) compared to normal tissue. A higher expression level associated aggressive pathological characteristics, including deep invasion, poor differentiation and lymph node metastases. two cell lines, BGC823 SGC7901, were both epithelial (GES-1). Moreover, the even BGC823/DR SGC7901/DR cells are resistant paclitaxel or adriamycin. knockdown inhibited proliferation promoted apoptosis cells. The invasion also significantly measured by Transwell assay. addition, restored chemosensitivity This decreased multidrug (MDR1) protein. Taken together, our data suggest lncRNA correlated characteristics GC, it may serve as oncogene regulate proliferation, chemoresistance GC